| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
body size and weight | Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
histopathology | Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. | inbred (28) | both | 87wks | 2011 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content. | inbred (5) | both | 12, 24, 52 wks | 2008 |
|
|
glucose tolerance | 0 to 180 min after 20% glucose i.p. 16h fast. | inbred (4) | both | 12, 24, 52 wks | 2008 |
|
|
body weight | Body weight | inbred (14) | both | 25wks | 2009 |
|
|
intake monitoring | Food intake, water intake at 6mo. Light phase, dark phase, total. | inbred (14) | both | 25wks | 2009 |
|
|
monitoring system | Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. | inbred (14) | both | 25wks | 2009 |
|
|
histopathology | Kidney pathology at 20mo. | inbred (23) | both | 87wks | 2014 |
|
|
body weight | Various interventions vs. controls. | UM-HET3 population | both | various | 2004-2022 |
|
|
colony observation | Life span study. Various interventions vs. controls. | UM-HET3 population | both | various | 2004-2022 |
|
|
DXA | Body composition. Body mass, fat mass, lean mass, water content. Intervention vs. controls. | UM-HET3 population | both | various | 2004-2022 |
|
|
glucose tolerance | Postprandial glucose. Invervention vs. controls. | UM-HET3 population | both | various | 2004-2022 |
|
|
grip strength | Interventions vs. controls. | UM-HET3 population | both | various | 2004-2022 |
|
|
histopathology | Pathology. Percent lesions in liver degeneration, lung tumor, renal organs. Intervention vs. controls. | UM-HET3 population | both | various | 2004-2022 |
|
|
rotarod | Interventions vs. controls. | UM-HET3 population | both | various | 2004-2022 |
|
|
uterus weight | Uterus weight, ovariectomy study with and without an intervention. | UM-HET3 population | both | various | 2004-2022 |
|
|
ABR test | Auditory brainstem response. | KOMP | both | 66-81wks | 2021 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | KOMP | both | 66-81wks | 2021 |
|
|
complete blood count | Hematology parameters. | KOMP | both | 66-81wks | 2021 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | KOMP | both | 66-81wks | 2021 |
|
|
ECG | Heart rate and wave intervals. Conscious. | KOMP | both | 66-81wks | 2021 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 66-81wks | 2021 |
|
|
grip strength | 3 trials. | KOMP | both | 66-81wks | 2021 |
|
|
hole board test | Exploratory behavior. | KOMP | both | 66-81wks | 2021 |
|
|
light-dark box | Anxiety, avoidance behavior. 20 min test. | KOMP | both | 66-81wks | 2021 |
|
|
metabolic panel | Clinical blood chemistry (plasma). No fast. | KOMP | both | 66-81wks | 2021 |
|
|
observation (SHIRPA) | Behavior, and neurosensory responses (SHIRPA protocol). | KOMP | both | 66-81wks | 2021 |
|
|
open field test | Locomotor, exploratory, and anxiety-related behavior. 20 min test, some at 5 min intervals. | KOMP | both | 66-81wks | 2021 |
|
|
ophthalmoscopy | Eye morphology. | KOMP | both | 66-81wks | 2021 |
|
|
organ weights | Heart weight. Raw and normalized to body weight. | KOMP | both | 66-81wks | 2021 |
|
|
slit lamp | Eye morphology. | KOMP | both | 66-81wks | 2021 |
|
|
Y-maze | Spontaneous alternation and other parameters. 8 min test. | KOMP | both | 66-81wks | 2021 |
|
|
ABR test | Auditory brainstem response. | inbred (51) | both | 3-12wks and 15-72wks | 2000 |
|
|
ABR test | Auditory brainstem response. | B6.A consomic w/par (24) | both | 23-30wks | 2012 |
|
|
ABR test | Auditory brainstem response. | B6.PWD consomic w/par (28) | both | 49-63wks | 2012 |
|
|
urinalysis | Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. | inbred (30) | both | 52, 78, 104 wks | 2008 |
|
|
histopathology | Kidney pathology. Aging study, 6mo, 12mo, 20mo. | inbred (29) | m | 52, 78, 104 wks | 2013 |
|
|
apoptosis assessment | Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
chromosome instability assessment | Chromosome instability. Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
body weight
with restricted diet |
Restricted diet vs. ad libitum diet. | ILSXISS (44) | both | max lifespan | 2010 |
|
|
colony observation
with restricted diet |
Life span comparison. Restricted diet vs. ad libitum diet. | ILSXISS (44) | both | max lifespan | 2010 |
|
|
NMR
with restricted diet |
Body mass, fat mass, lean mass. Restricted diet vs. ad libitum diet. | ILSXISS (44) | both | max lifespan | 2010 |
|
|
balance beam | Time to cross narrow beam, age 6 and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
behavior observation | Sensorimotor composite score, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
biomarker quantification | Temporal cortex amyloid level, age 6 and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
body weight | Measured every 2 mo, starting at age 2 mo to 16 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
elevated plus maze | Distance traveled and arm entries, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
fear conditioning test | Time spent freezing, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
grip strength | Grip strength across 3 trials, age 6 mo and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
inclined screen test | Time to right body, age 6 and 14 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
Y-maze | Spontaneous alternation and other parameters measured every 2 mo, from age 2 to 16 mo. | F1 AD-BXD (55) | both | 7-65wks | 2019 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (30) | both | 26, 52, 78, 104 wks | 2007 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
immune cell quantification | Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
histopathology | Cell proliferation in the rostral migratory stream. BrdU+ cells. | inbred (9) | both | 13-78wks | 2013 |
|
|
gait analysis | Aging study, 6mo, 18mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
grip strength | Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
study archive | Histopathology. Aging study. | inbred (28) | both | 2008 | |
|
|
ECG | Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. | inbred (29) | both | 26, 52, 87 wks | 2008 |
|
|
gait analysis | Aging study, 6mo, 12mo, 18mo. | inbred (31) | both | 26, 52, 78 wks | 2010 |
|
|
body weight | Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
hormone quantification | Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
colony observation | Life span study. Survival curves. Aging study. | inbred (31) | both | max lifespan | 2007 |
|
|
lipid profile | Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
metabolic panel | Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
colony observation | Observed age at vaginal opening (patency). Aging study. | inbred (33) | f | 2-9wks | 2009 |